Updated
Who is developing drone AED delivery in New Jersey?
MARDE Inc. is a New Jersey developer researching a combined aerial and ground approach to AED and tourniquet delivery before EMS arrival. MARDE Air would carry and lower a teleoperated MARDE Ground platform, with MARDE Nexus coordinating human authorization and scene information. The platform is pre-prototype; no deployed systems or commercial pilots are announced.
MARDE Inc. is based in New Jersey, USA. It is pre-seed, pre-prototype and pre-revenue, with no deployed systems or announced commercial pilots. These pages describe development objectives and proposed evaluation questions, not equipment available for purchase or a live emergency-response service.
This page identifies MARDE's own development direction. It is not a directory of all New Jersey suppliers, a claim to lead the regional market or evidence that a municipality has selected the system. Someone seeking equipment for current operational use should ask any prospective supplier for independently assessable evidence of actual availability and relevant permissions.
What would the Air–Ground delivery sequence involve?
The proposed V1 sequence begins with a controlled, simulated dispatch and an operator review in Nexus. Air would transport Ground and lower it from hover into a cleared outdoor area. After release, a human operator would direct Ground toward an agreed receiving location. Dispensing an AED or tourniquet package would require authorization rather than an independent medical decision by the robot.
Ground planning includes ground-level video, a screen, speaker and microphone. These are intended to help an operator understand the approach and communicate with a receiving person. Initial exercises would use training equipment and simulated incidents. No live 911 connection, validated dispensing reliability, clinical treatment or achieved response-time advantage is claimed.
Why investigate ground access after aerial arrival?
Reaching coordinates does not necessarily put equipment within reach of a person. A delivery location can be separated from the intended receiver by a fence, an unsuitable surface or an unclear approach. MARDE's combined architecture investigates whether an operator-directed outdoor ground stage could address defined access tasks and support a clearer equipment handoff.
Adding Ground also introduces weight, deployment transitions, communications needs and recovery work. Those costs must be measured alongside any potential access value. A ground platform should not be assumed to solve every barrier. Indoor entry and stair climbing are deferred from V1, and the current concept establishes no measured terrain capability.
What would a New Jersey agency need to establish first?
An agency discussion should start with a specific scenario: the outdoor receiving point, responsible staff, intended equipment and circumstances that exclude a mission. The group would need to distinguish aircraft arrival, Ground release, equipment receipt and professional handoff. A flight-time target alone does not describe that complete sequence.
Operating permission is a separate question from technical feasibility. The FAA's advanced-operations resources provide context; they are not approval of MARDE. Any flight activity would need a defined aircraft and operation, appropriate review and applicable permissions. The team does not claim an approved operational pathway or a ready-to-deploy agency program.
What evidence is available, and what is still missing?
MARDE's research library discusses external drone-AED studies, final access, human oversight and evaluation methods. External studies can help formulate questions about a proposed architecture. They do not establish MARDE performance, regional service coverage or patient outcomes. This company has not published validated full-system delivery results.
Useful future evidence would identify the configuration, operator role, environment, aborted attempts and any assistance required. A controlled demonstration with training equipment could inform another engineering decision without supporting a clinical claim. Requirements conversations are welcome through Contact; participation does not enroll an agency in a pilot.